DMRA
Damora Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$21.49Close
$34.3MMarket cap
$4.95 – $34.1452-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Far from its high 37% below its 52-week high
- Distribution down-day volume 1.5× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
37%
1wk
up 1.9%
price change
1mo
up 1.0%
price change
12-month return
up 192%
market up 11% ·
its own up 177%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.1×
price / book
Earnings yield
—
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 164%
return on equity
Free cash margin
—
-$6.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
7.1%
$1.53 a day · 2×ATR $18.42
RS
78 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.65
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- At least 30% above the 52-week low: passes
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 21.3% over the year, from 1m to 2m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Mar 10, 2026
Last shock
Sep 15, 2026-13% in one session3.9× volumeno filing matched-13% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$33.6M | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$210.9M |
| Net income | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Earnings per share | — | -$2.05 | -$2.43 | -$1.44 | -$18.53 | -$153.95 |
| Free cash flow | -$38.2M | -$52.5M | -$43.1M | -$36.9M | -$18.6M | -$6.7M |
| Cash | $163.6M | $62.6M | $32.8M | $21.5M | $14.2M | $257.6M |
| Shareholders' equity | $165.5M | $117.2M | $61.8M | $32.3M | $15.8M | $240.4M |
| Shares outstanding | 25.26m | 25.26m | 25.65m | 27.11m | 1.32m | 1.60m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 19, 2026 | Annual ↗ | Dec 31, 2025 | 78d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 19, 2025 | Annual ↗ | Dec 31, 2024 | 78d |
| Nov 1, 2024 | Quarterly ↗ | Sep 30, 2024 | 32d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| Apr 29, 2024 | Quarterly ↗ | Mar 31, 2024 | 29d |
| Mar 8, 2024 | Annual ↗ | Dec 31, 2023 | 68d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 20, 2026 | Material agreement · Holder rights changed · Charter or bylaws · Regulation FD ↗ |
| Jun 17, 2026 | Shareholder vote ↗ |
| May 4, 2026 | Director or officer change ↗ |
| Apr 20, 2026 | Auditor change ↗ |
| Mar 23, 2026 | Director or officer change · Regulation FD ↗ |
| Mar 10, 2026 | Results · Charter or bylaws · Regulation FD ↗ |
| Feb 11, 2026 | Material agreement ↗ |
| Feb 10, 2026 | Director or officer change · Charter or bylaws · Other events ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Jan 6, 2026 | Unregistered share sale · Director or officer change ↗ |
| Nov 10, 2025 | Material agreement · Acquisition or disposal · Unregistered share sale · Director or officer change · Charter or bylaws · Regulation FD ↗ |
| Jun 20, 2025 | Shareholder vote ↗ |